



PRESS RELEASE

This information was submitted for disclosure on 23 April 2015 at 16.45 (cet).

Probi's Annual General Meeting 2015

On Probi's Annual General Meeting on 23 April, 2015, the following was resolved:

- The Annual General Meeting approved the Annual Report and the Board's proposal for a dividend for the financial year 2014 corresponding to 0.85 SEK per share. The record date was set for April 27, 2015.
- The Annual General Meeting discharged the Board and the CEO from liability for the financial year 2014.
- The board shall consist of six members without any deputies. Re-elected members were Jörn Andreas, Benedicte Fossum, Jan Nilsson and Eva Redhe Ridderstad. Newly elected was Jean-Yves Parisot and Jonny Olsson. Jean-Yves Parisot was elected as Chairman of the Board. All in accordance with the nomination committee's proposal.
- The board fee was decided to a total of 1,175,000 SEK, whereof 300,000 SEK to the chairman and 175,000 SEK to each of the other members.
- Re-election of the registered public accounting firm Deloitte AB, and Per-Arne Pettersson as principal auditor.
- The board's proposal regarding guidelines for remuneration of senior executives was approved.
- The Probi nomination committee shall consist of three shareholder representatives and the Annual General Meeting selected Heinz-Jürgen Bertram (Symrise), Jannis Kitsakis (4:e AP-fonden) and Bengt Jeppsson (Professor, Surgical Faculty, Lund University).

The CEO's presentation will be available on www.probi.se.

The information is such that Probi AB must disclose in accordance with the Swedish Securities Market Act and/or the Financial Instruments Trading Act.

FOR FURTHER INFORMATION, CONTACT:

Peter Nählstedt, CEO, Probi, tel +46 46 286 89 23 or mobile +46 723 86 99 83, e-mail: peter.nahlstedt@probi.se

ABOUT PROBI

Probi AB is a Swedish publicly traded bioengineering company that develops effective and well-documented probiotics. Through its world-leading research, Probi has created a strong product portfolio in the gastrointestinal health and immune system niches. Probi's products are available to consumers in more than 30 countries worldwide. Probi's customers are leading food, health-product and pharmaceutical companies in the Functional Food and Consumer Healthcare segments. In 2014, Probi had sales of MSEK 135. The Probi share is listed on NASDAQ OMX Stockholm, Small Cap. Probi has about 3,000 shareholders. Read more at www.probi.se